Heart and Vascular
ACT-EARLY
Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)
Contact Research Team:
[email protected]
Site principal investigator:
Brett Sperry, MD
Learn more about this study:
NCT06563895